Influencing factors of coagulation abnormalities induced by cefoperazone sodium and sulbactam sodium in patients with ischemic cerebrovascular disease

doi:10.19803/j.1672-8629.2022.01.19

Abstract

Abstract: Objective To investigate the influencing factors of coagulation abnormalities induced by cefoperazone sodium and sulbactam sodium in patients with ischemic cerebrovascular disease. Methods The clinical data on 102 patients with ischemic cerebrovascular disease treated with cefoperazone sodium and sulbactam sodium in our hospital between January 1, 2015 and September 30, 2019 was retrospectively analyzed. The basic information, medications, liver and kidney function parameters, serum albumin levels and coagulation function parameters were recorded and analyzed using binary logistic regression analysis. Results The incidence of coagulation abnormalities was 42.16% (43/102). Logistic analysis showed that the number of days cefoperazone sodium and sulbactam sodium were used and serum levels of creatinine and albumin were independent risk factors for coagulation abnormalities in patients with ischemic cerebrovascular disease (P<0.05). Conclusion Ischemic cerebrovascular disease complicated with renal insufficiency and hypoalbuminemia could increase the risk of coagulation abnormalities induced by cefoperazone sodium and sulbactam sodium. The incidence of coagulation abnormalities increases with the number of days cefoperazone sodium and sulbactam sodium are used. Therefore, coagulation function should be monitored.

Key words: cefoperazone sodium and sulbactam sodium, coagulation abnormalities, influencing factors, ischemic cerebrovascular disease

CLC Number:

LIANG He, MENG Guangyi, ZHONG Liqiu, ZHOU Lijuan, PANG Jiarong. Influencing factors of coagulation abnormalities induced by cefoperazone sodium and sulbactam sodium in patients with ischemic cerebrovascular disease[J]. Chinese Journal of Pharmacovigilance, 2022, 19(1): 87-90.

References

[1] VERMA AA, GUO Y, KWAN JL, et al.Patient characteristics, resource use and outcomes associated with general internal medicine hospital care: the General Medicine Inpatient Initiative (GEMINI)retrospective cohort study[J]. CMAJ Open,2017,5(4):E842-E849.
[2] SUN SM, ZHANG Z, WANG YQ.Clinical analysis of cefoperazone/sulbactam in the treatment of pulmonary infections in stroke patients[J]. Chinese Journal of Nosocomiology(中华医院感染学杂志), 2015, 25(7): 1536-1537, 1540.
[3] JIANG H, CHENG JX, QUAN C, et al.Effects of cefoperazone sodium/sulbactam sodium on coagulation function and its intervention[J]. Pharmaceutical Care and Research(药学服务与研究), 2016, 16(4): 300-303.
[4] WU B, DAI XQ, ZHANG CH, et al.Effect of sulbactam-cefoperazone on coagulation function and the intervention[J]. Chinese Journal of Critical Care Medicine(中国急救医学), 2013, 33(3): 228.
[5] Chinese Society of Neurology, Chinese Stroke Society. Diagnostic criteria of cerebrovascular diseases in China (version 2019)[J]. Chinese Journal of Neurology(中华神经科杂志), 2019, 52(9): 710-715.
[6] CHEN WB, PAN XL.Diagnostics(诊断学)[M]. 7th ed. Beijing: People's Health Publishing House, 2008: 301-302.
[7] WONG RS, CHENG G, CHAN NP, et al.Use of cefoperazone still needs a caution for bleeding from induced vitamin K deficiency[J]. Am J Hematol, 2006, 81(1): 76.
[8] SCHÄFER H, NABER K, ADAM D. Hemostasis disturbance caused by cephalosporins with an N-methylthiotetrazole side chain: a randomized pilot study[J]. Arzneimittel-forschung, 1989, 39(9):1156-1162.
[9] SHEARER MJ, BECHTOLD H, ANDRASSY K, et al.Mechanism of cephalosporin-induced hypoprothrombinemia: relation to cephalosporin side chain, vitamin K metabolism, and vitamin K status[J]. J Clin Pharmacol, 1988, 28(1): 88-95.
[10] PANG LF.One case of coagulation abnormalities induced by cefoperazone sodium and sulbactam sodium for injection[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2018, 15(5): 312-313.
[11] Chinese expert consensus group on diagnosis and treatment of stroke associated pneumonia. Chinese expert consensus on diagnosis and treatment of stroke associated pneumonia[J]. Chinese Journal of Internal Medicine(中华内科杂志), 2010, 49(12): 1075-1078.
[12] ZHANG HY, WU D, WANG GX, et al.Analysis of clinical factors for coagulation abnormalities induced by cefoperazone-sulbactam in clinical patients[J]. Chinese Medical Record(中国病案), 2019, 20(6): 81-84.
[13] LIANG B, SU ZR.The impact of elevated serum creatinine on the curative effectiveness and prognosis of acute myocardial infarction[J]. Chinese Journal of Integrative Medicine on Cardio/Cerebrovascular Disease(中西医结合心脑血管病杂志), 2014, 7: 892-893.
[14] DU JL, JIAO HM, SUN D.Analysis of relative factors for coagulation abnormalities induced by cefoperazone/sulbactam in elderly patients[J]. The Chinese Journal of Clinical Pharmacology(中国临床药理学杂志), 2016, 32(24): 2303-2306.
[15] Expert consensus committee on clinical application of β- lactam antibiotics / β- lactamase inhibitor mixture. Expert consensus on clinical application of β- lactam antibiotics / β- lactamase inhibitor mixture[J]. National Medical Journal of China(中华医学杂志), 2015, 95(48): 3887-3894.
[16] LI DR, GAO WB, ZHU JH.3 cases of disfunction of blood clotting induced by cefoperazone sulbactam sodium[J]. Chinese Journal of Emergency Medicine(中华急诊医学杂志), 2018, 27(5): 555-557.
[17] WANG Y, DING N.Clinical analysis and countermeasures of cefoperazone sodium and sulbactam sodium-induced coagulation abnormalities[J]. Journal of Clinical and Experimental Medicine(临床和实验医学杂志), 2015, 14(16): 1397-1399.
[18] SHI SP, WU X, NONG JC, et al.Influencing factors of coagulation abnormalities induced by cefoperazone/sulbactam[J]. Chinese Journal of Pharmacoepidemiology(药物流行病学杂志), 2019, 28(9): 578-580, 590.
[19] DAI XQ, MA CX, CAI Y, et al.Risk factor analysis and nursing of coagulant function abnormality caused by cefoperazone sodium and sulbactam sodium[J]. Journal of Nursing(护理学报),2013, 9: 59-61.